ghadmin

May 16, 2023

Guardant Health Releases Inaugural ESG Report

The publication of its inaugural Environmental, Social & Governance (ESG) Report, which provides information related to key ESG commitments that the company has laid out as part of its business strategy

May 9, 2023

Guardant Health presents additional information from ECLIPSE study at 2023 Digestive Disease Week on the performance of Shield™ blood test

Shield ™ blood test achieved overall 83% sensitivity and 90% specificity and demonstrated early-stage detection in range with other guideline-recommended non-invasive CRC screening modalities

May 8, 2023

Guardant Health Announces Additions to Leadership Team

At Guardant, we have built one of the most transformative platforms in diagnostics and we think extensively about how we get work done more efficiently, from development through delivery, to fulfill our primary mission of helping patients

May 2, 2023

Why 80% in Every Community Matters

During my first semester in college, I took one of the most difficult exams of my life thus far. As my professor passed back our graded tests, he mentioned the average was 90%. But when he handed me my exam – my heart sank as I realized I received a 68% – a ‘D’. In a class of hundreds of students, I felt isolated, while most of my colleagues celebrated. Although the 90% average was an important way of representing the class data, it did not tell the whole story – particularly, the story of individuals such as myself who did not do well. This concept is not just seen in school – it can also be seen in other areas, such as in healthcare.

April 25, 2023

Guardant Health and Parker Institute for Cancer Immunotherapy (PICI) launch research collaboration to study connection between cancer biomarkers and immunotherapy treatment response

Project will identify genomic and epigenomic biomarkers in patient blood samples from PICI’s RADIOHEAD study using GuardantINFINITY™

April 21, 2023

Guardant Health announces new data to be presented at 2023 Digestive Disease Week showcasing the potential of its blood-based technology to detect colorectal cancer

The data from the pivotal ECLIPSE Study accepted as a late-breaking abstract highlights the performance of the Shield ™ blood test in detecting colorectal cancer in asymptomatic patients

April 19, 2023

Guardant Health to Report First Quarter 2023 Financial Results on May 9, 2023

Live audio of the webcast will be available on the “Investors” section of the company website. The webcast will be archived and available for replay after the event.

April 18, 2023

Guardant Health Receives Medicare Coverage for Guardant360 Response™ to Monitor Cancer Patient Response to Immunotherapy

First blood-only liquid biopsy test for monitoring molecular response to immune checkpoint inhibitors now covered for US Medicare patients with metastatic or inoperable solid tumors

April 14, 2023

Patients Don’t Want Colonoscopies – Let’s Give Them Something Better

The life-saving potential of alternative screening methods for colorectal cancer

April 11, 2023

Guardant Health to Present Data From 14 Studies Highlighting Advances in Precision Oncology and Cancer Screening at 2023 AACR Annual Meeting

New research demonstrates value of epigenomic analysis and methylation sequencing capabilities of GuardantINFINITY™ platform for biomarker discovery, therapy selection and response monitoring